Skip to Content

CureVac NV Ordinary Shares CVAC Stock Quote

| Rating as of


Last close prices updated as of Feb 07, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 10.58
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 8.76  –  9.99
  • Year Range 5.63  –  20.49
  • Market Cap 1.7849 Bil
  • Volume / Avg 3.5 Mil /  880,957.9
  • Price / Sales 18.99
  • Price / Book 3.06
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CVAC

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

Economic Moat


Capital Allocation


CureVac Focuses on Expanding Pipeline Through Enhanced Oncology Strategy; Maintaining $15.40 FVE

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

CureVac was founded in 2000, and its focus is on developing vaccines and therapies using messenger ribonucleic acid, or mRNA. mRNA offers several advantages, including cell-free, rapid, large-scale manufacturing and the ability to substitute new genetic sequences to create novel vaccines. Vaccines are typically composed of weakened viruses or proteins (antigens) that they express. In mRNA vaccines, the genetic code for an antigen is administered to patients who then manufacture the antigen themselves, which triggers an immune response.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CVAC

Company Profile CVAC

Business Description

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac’s first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

Friedrich-Miescher-Strasse 15
Tubingen, BW, 72076, DEU
Industry Biotechnology
Employees 1,000

Related Articles CVAC

FAQs for CureVac NV Ordinary Shares Stock

No. CVAC does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CVAC’s market cap is 1.78 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CVAC’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CVAC’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CVAC’s historical performance against its industry peers and the overall market.